免疫組織化學 (IHC) 市場 - 全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、最終用戶、地區、競爭格局分類，2021-2031 年

全球免疫組織化學 (IHC) 市場預計將從 2025 年的 27.1 億美元成長到 2031 年的 40.7 億美元，複合年成長率為 7.01%。

免疫組織化學 (IHC) 是一種重要的顯微鏡技術，它利用抗體來識別組織切片中的特定抗原，用於疾病的鑑定和研究。這一市場擴張的主要驅動力是全球癌症發病率的上升以及對精準生物標記分析所需的個人化醫療需求的日益成長。不斷加重的疾病負擔使得使用 IHC 檢測進行精準組織病理學評估的需求持續存在。例如，美國癌症協會估計，到 2025 年，美國將新增 2,041,910 例癌症病例，凸顯了對可靠的病理學解決方案以指導治療策略的迫切需求。

市場促進因素

免疫組織化學 (IHC) 市場的主要促進因素是全球癌症和慢性疾病發生率的不斷上升，這必然導致對組織切片檢查分析的需求增加。不斷成長的患者群體給病理​​檢查室帶來了更大的壓力，需要精確的組織學檢查以識別惡性腫瘤和腫瘤起源，從而導致 IHC 抗體、試劑和染色平台的消耗量增加。這一趨勢要求國際醫療保健系統擴大診斷服務的覆蓋範圍，以有效應對日益成長的疾病負擔。全球對可靠的 IHC 檢測的臨床需求正在不斷成長，加拿大預計 2024 年將新增 247,100 例癌症病例，證明了這一點。同時，隨著伴隨診斷在藥物研發中日益普及，免疫組織化學 (IHC) 也被整合到標靶治療製劑中，市場也正在轉型。製藥公司越來越依賴 IHC 檢測來識別適合特定生物製藥製劑）的患者，這使得該技術在臨床實踐中（而不僅僅是研究）變得至關重要。根據個人化醫療聯盟的說法，這種策略轉變體現在個人化醫療中，個人化醫療將在 2023 年佔新藥認證總數的三分之一以上，並且正在推動商業活動，羅氏等主要公司報告稱診斷藥物銷售額大幅成長。

市場挑戰

全球免疫組織化學 (IHC) 市場擴張的主要障礙在於自動化染色平台和專用試劑所需的大量資本投入。先進診斷基礎設施的高昂初始成本主要影響發展中地區的小規模檢查室和醫療機構，這些機構往往缺乏購買必要設備的預算。這一經濟障礙阻礙了精準組織病理學評估的廣泛應用，造成診斷能力的差異，並限制了新興經濟體（尤其是疾病負擔沉重的經濟體）的市場滲透率。此外，不一致且不斷縮減的報銷機制也顯著降低了採用這些診斷工具的經濟可行性。病理服務報銷額的下降迫使檢查室推遲昂貴的升級，例如購買先進的 IHC 系統。美國臨床病理學會 (ASCP) 在 2025 年醫生報銷方案中報告的平均支付率下降了 2.8%，這就是這種經濟壓力的一個例證。此類補償削減，加上營運成本增加，將擠壓利潤率，限制服務提供者投資關鍵診斷技術的能力，並最終阻礙整體市場成長。

市場趨勢

人工智慧 (AI) 與數位病理學的融合正在從根本上改變全球免疫組織化學 (IHC) 市場，顯著提升工作流程效率和診斷準確性。檢查室正從人工玻片分析轉向數位化平台，在這些平台上，AI 演算法能夠以比人工評估更高的重複性量化生物標記的表達。這項技術變革透過自動化常規玻片篩檢，有助於緩解病理學家短缺的問題，從而縮短複雜癌症診斷的周轉時間。數位病理系統的採用率已達到約 10%，顯示診斷方式正顯著轉向技術主導。同時，免疫腫瘤學中對腫瘤微環境進行詳細分析的需求，也推動了對多重免疫組織化學 (IHC) 檢測的需求，進而重塑市場格局。與傳統的單標記染色不同，多重檢測能夠在單一組織切片上同時檢測多種不同的生物標記物，從而深入了解免疫細胞的組織結構和相互作用。這項功能對於查核點抑制劑的研發和配製至關重要，促使研究機構和製藥公司對先進的染色解決方案進行了大量投資。耗材銷售額年增13%也印證了這一趨勢，凸顯了高參數組織分析試劑需求的成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球免疫組織化學（IHC）市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類型（抗體、儀器、試劑、試劑盒）
  • 依應用領域（診斷、癌症、感染疾病、心血管疾病、自體免疫疾病、糖尿病、腎臟疾病、研究）
  • 依最終使用者（醫院/診斷檢查室、研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美免疫組織化學（IHC）市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲免疫組織化學（IHC）市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區免疫組織化學（IHC）市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲免疫組織化學（IHC）市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲免疫組織化學（IHC）市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球免疫組織化學（IHC）市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer US LLC
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

The global Immunohistochemistry Market is anticipated to expand from USD 2.71 Billion in 2025 to USD 4.07 Billion by 2031, exhibiting a CAGR of 7.01%. Immunohistochemistry (IHC) is a vital microscopic diagnostic method employing antibodies to pinpoint specific antigens in tissue sections for disease identification and research purposes. The market's expansion is predominantly fueled by the increasing worldwide prevalence of cancer and the growing adoption of personalized medicine, which demands accurate biomarker analysis. This escalating disease burden sustains the ongoing need for precise histopathological evaluations offered by IHC assays. For instance, the American Cancer Society estimates 2,041,910 new cancer diagnoses in the U.S. in 2025, underscoring the critical requirement for robust pathology solutions to guide treatment strategies.

Market Driver

The primary driver for the Immunohistochemistry Market is the escalating global incidence of cancer and chronic diseases, which inherently increases the demand for tissue biopsy analysis. The growing patient population intensifies pressure on pathology laboratories to conduct precise histological examinations for malignancy and tumor origin, thus boosting the consumption of IHC antibodies, reagents, and staining platforms. This trend mandates wider diagnostic access within international healthcare systems to effectively manage the rising disease burden, as evidenced by an estimated 247,100 new cancer cases projected in Canada for 2024, highlighting the expanding global clinical need for robust IHC testing. Simultaneously, the growing integration of companion diagnostics in drug development is transforming the market by embedding immunohistochemistry into targeted therapy prescription. Pharmaceutical firms increasingly depend on IHC assays to identify suitable patients for specific biologic treatments, such as those targeting HER2 or PD-L1 markers, elevating the technique to a critical clinical necessity beyond research. This strategic shift is reflected in personalized medicines comprising over one-third of new drug approvals in 2023, according to the Personalized Medicine Coalition, and sustains commercial activities, with major players like Roche reporting significant diagnostics sales.

Market Challenge

A significant impediment to the global immunohistochemistry market's expansion is the substantial capital investment needed for automated staining platforms and specialized reagents. The high upfront costs associated with advanced diagnostic infrastructure primarily impact smaller laboratories and healthcare facilities in developing regions, which often lack the budget to acquire essential instrumentation. This financial barrier hinders the broad adoption of precise histopathological assessments, creating diagnostic capability disparities and restricting market penetration in emerging economies with high disease burdens. Moreover, inconsistent and decreasing reimbursement schemes severely undermine the financial feasibility of implementing these diagnostic tools. Reduced compensation for pathology services compels laboratories to postpone costly upgrades like advanced IHC systems. This financial pressure is exemplified by the American Society for Clinical Pathology's report of a 2.8 percent reduction in average payment rates for the 2025 Physician Fee Schedule. Such reimbursement cuts, alongside rising operational expenses, compress profit margins, thereby limiting service providers' ability to invest in crucial diagnostic technologies and ultimately impeding overall market growth.

Market Trends

The integration of Artificial Intelligence (AI) in digital pathology is fundamentally transforming the global Immunohistochemistry Market by boosting workflow efficiency and diagnostic accuracy. Laboratories are increasingly moving from manual glass slide analysis to digital platforms, enabling AI algorithms to quantify biomarker expression with greater reproducibility than human assessment. This technological shift helps alleviate the pathologist shortage by automating routine slide screening, thereby accelerating turnaround times for intricate cancer diagnoses. The adoption rate of digital pathology systems has reached around 10 percent, signaling a significant move towards technology-driven diagnostics. Concurrently, the rising demand for multiplex immunohistochemistry assays is also reshaping the market, driven by the necessity to thoroughly profile the tumor microenvironment in immuno-oncology. Unlike conventional single-marker staining, multiplexing allows for the simultaneous detection of multiple distinct biomarkers on a single tissue section, offering detailed insights into immune cell organization and interactions. This capability is crucial for developing and prescribing checkpoint inhibitors, prompting substantial investment in advanced staining solutions from research institutions and pharmaceutical developers. This trend is evidenced by a 13 percent year-over-year increase in consumables revenue, highlighting the growing consumption of reagents for high-parameter tissue analysis.

Key Market Players

• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer U.S. LLC
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited

Report Scope

In this report, the Global Immunohistochemistry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunohistochemistry Market, By Product

• Antibodies
• Equipment
• Reagents
• Kits

Immunohistochemistry Market, By Application

• Diagnostics
• Cancer
• Infectious Diseases
• Cardiovascular Diseases
• Autoimmune Diseases
• Diabetes Mellitus
• Nephrological Diseases
• Research

Immunohistochemistry Market, By End User

• Hospitals & Diagnostic Laboratories
• Research Institutes
• Others

Immunohistochemistry Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunohistochemistry Market.

Available Customizations:

Global Immunohistochemistry Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunohistochemistry Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Antibodies, Equipment, Reagents, Kits)
  • 5.2.2. By Application (Diagnostics, Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Diabetes Mellitus, Nephrological Diseases, Research)
  • 5.2.3. By End User (Hospitals & Diagnostic Laboratories, Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Immunohistochemistry Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunohistochemistry Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Immunohistochemistry Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Immunohistochemistry Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Immunohistochemistry Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunohistochemistry Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Immunohistochemistry Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Immunohistochemistry Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Immunohistochemistry Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Immunohistochemistry Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Immunohistochemistry Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Immunohistochemistry Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Immunohistochemistry Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Immunohistochemistry Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Immunohistochemistry Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Immunohistochemistry Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Immunohistochemistry Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Immunohistochemistry Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Immunohistochemistry Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Immunohistochemistry Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Immunohistochemistry Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Immunohistochemistry Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Immunohistochemistry Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Immunohistochemistry Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Immunohistochemistry Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Merck KGaA
• 15.4. Danaher Corporation
• 15.5. PerkinElmer U.S. LLC
• 15.6. Bio-Rad Laboratories, Inc.
• 15.7. Cell Signaling Technology, Inc.
• 15.8. Bio SB
• 15.9. Agilent Technologies, Inc.
• 15.10. Abcam Limited

16. Strategic Recommendations

17. About Us & Disclaimer